公开(公告)号：US20220098279A1

公开(公告)日：2022-03-31

申请号：US17426886

申请日：2020-01-29

Applicant: Amgen Inc.

Inventor： Quanzhou LUO ,  Scott KUHNS ,  Diana WOEHLE ,  Matthew JERUMS ,  XueJun HAN ,  Kelli M.G. MATTHIES

IPC: C07K14/71 ,  C07K1/16

Abstract: The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.

公开(公告)号：US20240417442A1

公开(公告)日：2024-12-19

申请号：US18798878

申请日：2024-08-09

Applicant: Amgen Inc.

Inventor： Quanzhou LUO ,  Scott KUHNS ,  Diana WOEHLE ,  Matthew JERUMS ,  XueJun HAN ,  Kelli M.G. MATTHIES

IPC: C07K14/71 ,  C07K1/16

Abstract: The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.

公开(公告)号：US20210079065A1

公开(公告)日：2021-03-18

申请号：US17040422

申请日：2019-03-26

Applicant: AMGEN INC.

Inventor： Prince BHEBE ,  Matthew JERUMS ,  Irene LIU ,  Kurt KUNAS

IPC: C07K16/00 ,  C12P21/00 ,  C07K16/30

Abstract: Provided herein are methods of producing an antibody composition comprising a desired or predetermined or pre-selected level of total afucosylated (TAF) glycoforms. In exemplary embodiments, the method comprises maintaining glycosylation-competent cells in a cell culture medium comprising fucose and/or glucose at a specific concentration as described herein, depending on the level of TAF glycoforms desired. Related compositions comprising glycosylated proteins and TAF glycoforms thereof are also provided herein. Also provided are cell culture media.